Biosimilars at Kaiser Permanente: Lessons in successfully reducing spending on prescription drugs
Biosimilars play a critical role in lowering drug prices. Kaiser Permanente successfully uses biosimilars to improve affordability for our members. We are eager to share best practices and work with policymakers to help facilitate a more competitive market for biologic…
Building Racial Equity into the Drug Development System: Clinical Trials, Access, and Affordability
This webinar is the second in a two-part series that looks at racial equity in the drug development system, from investment all the way through access. This forum will focus on equity in the patent system, clinical trials, healthcare delivery, and affordability.
Building a bigger table for a more equitable drug development system
On December 7, 2020, the Kaiser Permanente Institute for Health Policy hosted the first of a 2-part virtual forum examining racial equity in the drug development system, including during initial investments and research, patent and regulatory processes, supplier and physician…
The Medicaid Drug Rebate Program and the impact of “best price” rules
The Medicaid Drug Rebate Program (MDRP) requires pharmaceutical manufacturers to issue rebates to Medicaid for covered outpatient drugs. When they offer prescription drug benefits, Medicaid programs must cover nearly all drugs, potentially reducing Medicaid’s leverage to negotiate discounts. Policymakers created…
How to save the patent system in 3 easy steps
Patents are in the news as Congress considers legislation to address patent abuses and anticompetitive behavior by the pharmaceutical industry. If you’re tuning into these issues for the first time (or even the second or third) you’ll notice that there…
The price Is wrong: Why we need to curb prices on biologics to protect patients
I want to tell you a story about one of my patients — let’s call her Helen. After months of treatment, Helen just wasn’t getting better despite being prescribed a drug that I have used to successfully treat many of…
Our thoughts on HHS’s blueprint to lower drug prices: It’s time for a new legal and policy landscape
In May 2018, the U.S. Department of Health and Human Services (HHS) requested feedback on its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. By Murray Ross, PhD, Vice President and Institute for Health Policy Director.
Reflections on high drug pricing in America: Where we are and where we’re headed
Pulse Check on High Drug Pricing: Public Perception and Political Priorities. By Norman Ornstein, a resident scholar at the American Enterprise Institute and a contributing editor and writer at The Atlantic.
Addressing High Drug Pricing
Drug companies continue to raise prices to unaffordable levels, making it difficult for patients to access the medication they need to be healthy. This event brought together leaders from across sectors to discuss the drug pricing landscape and elevate effective policy solutions.